- LOGIN
- MemberShip
- 2026-05-09 09:58:29
- Company
- Gov purchased ₩200 billion worth of COVID-19 vaccines
- by Chon, Seung-Hyun Mar 23, 2022 05:51am
- The COVID-19 vaccine, which incorporates technology from domestic bio companies, will be supplied for the first time in Korea. SK Bioscience announced on the 21st that it has signed a pre-purchase contract with the KDCA for the COVID-19 vaccine worth 200 billion won. The contract volume is 10 million inoculations, and SK Bioscience will sequentially supply the amount according to the Korea Centers for Disease Control and Prevention's inoculation plan when the development of GBP510 is completed. GBP510 is a candidate substance for the COVID-19 vaccine jointly developed by SK Bioscience with IPD. GSK's immune-enhancing technology was also used. Phase 3 clinical trials are currently underway. SK Bioscience self-evaluated, "Korea's No. 1 COVID-19 vaccine, which checks the safety and effectiveness of Phase III clinical trials including Koreans, will be supplied in Korea." SK Bioscience independently produces and supplies two of the five major COVID-19 vaccines licensed in advanced countries such as the United States and the EU (AstraZeneca and Novavax) in Korea. SK Bioscience began consignment production of the undiluted and finished product of the COVID-19 vaccine AZD1222 developed by AstraZeneca last year, and this year, it supplied Nuvaxovid, a synthetic antigen-type COVID-19 vaccine with high safety and proven efficacy. GBP510 was selected for the Wave2 project of the international organization CEPI and is undergoing clinical trials with a total development cost of $213.7 million. In the first half of this year, it is planning to obtain a domestic item license, the WHO emergency license, and the EUA by overseas country. Recently, Rolling Review documents have been submitted to the MHRA for prompt approval. Ahn Jae-yong, president of SK Bioscience, said, GBP510 is the result of SK technology, the government's willingness to leap forward as a biopower, and the cooperation of global organizations supporting vaccine development for public health rights." Starting with GBP510, we will develop products to prepare for various viral infectious diseases and establish ourselves as a leading company in the global vaccine market, he said.
- Company
- Seqirus 'will introduce the first adjuvanted flu vaccine'
- by Mar 22, 2022 05:53am
- A multinational pharmaceutical company has bravely thrown its hat into the domestic influenza vaccine ring that is led by Korean companies such as GC Pharma and SK Bioscience, etc. The company, named Seqirus, is attempting to enter the Korean market equipped with the solid technology it accumulated through its sole focus on influenza vaccines. Seqirus is a vaccine company specializing in influenza vaccines that became the company it is after the influenza department of the Australia-based pharmaceutical company CSL acquired Novartis’s influenza vaccine business. The company has pursued vaccines, only influenza vaccines for over a century, and is known for its extensive influenza vaccine portfolio that covers a wide range of egg-based, cell culture-based, and adjuvanted vaccines. Its annual sales amount to ₩2 trillion. Seqirus's entrance into the Korean market was prompted by the rise of the COVID-19 pandemic after the sole manufacturer of cell-based vaccines in Korea, SK Bioscience, was unable to manufacture its influenza vaccines due to its manufacture of consigned COVID-19 vaccines. Thus, the Korean government granted emergency use authorization for Seqirus's cell culture-based flu vaccine ‘Flucelvax’ in Korea. Also, using the opportunity as momentum, Seqirus made the decision to start the direct supply of its egg-based Afluria that had been marketed through Boryung Biopharma until then. During an interview with Dailpharm, Jonathan Anderson, Medical Head of the International Region of Seqirus, said, “Although there are many excellent companies in Korea that already focus on the development and manufacture of influenza vaccines, Seqirus has strengths of owning various platforms in the area. As a research-based company, we are developing technology for cell culture-based vaccines, adjuvanted vaccines, and self-amplifying mRNA vaccines.” [Interview] Jonathan Anderson Medical Head of the International Region of Seqirus Among its various products, Seqirus has high expectations for its adjuvanted influenza vaccine ‘Fluad’ General flu vaccines can be less effective in immunocompromised elderly, or when the vaccine strain does not coincide with the epidemic, or due to egg-adaptations, etc. In such cases, adjuvanted flu vaccines can improve immune reaction and increase prevention. The ‘MF59’ used in Fluad is an adjuvant that had also been used in 2009 during the swine flu. ‘MF59’ is made using squalene that is produced in the liver, which induces an immune response in the injection site and promotes antigen uptake to increase immune response by activating T cells and B cells. In other words, the adjuvanted vaccine can achieve a strong antibody response even with a small amount. Anderson said, “Real-world results showed that the adjuvanted vaccine showed a better effect in elderly patients over the age of 65.” He added, “Many still get infected with influenza during the influenza season and progress to hospitalization or even death. With the social burden still high for influenza, adjuvanted vaccines could rise as a new alternative.” Anderson added that in terms of safety, the adjuvanted vaccine showed a higher rate of local reactions such as injection site pain than general vaccines, but the reactions were mostly mild or moderate and were resolved naturally over time. Based on its efficacy and safety data, Fluad was approved in 2020 in the US as the world’s first adjuvanted influenza vaccine allowed for use in people aged 65 years or older. Seqirus’s Korea, the Korean subsidiary of Seqirus is working to speed up the introduction of Fluad in Korea. As no adjuvanted flu vaccine exists in the Korean market yet, Fluad's approval by the MFDS is expected to change the domestic flu vaccine market. As Fluad has been introduced to Korea in the past, no separate clinical trial will be required for its introduction to Korea. Anderson said, “Seqirus plans to promptly introduce its vaccine portfolio to Korea. We will make the most effort to fully explain our data through close discussions with the healthcare authorities.
- Company
- GSK’s immuno-oncology drug Jemperli applies for approval
- by Eo, Yun-Ho Mar 22, 2022 05:53am
- Another immuno-oncology drug is set to soon be introduced to Korea. According to industry sources, GSK Korea has applied for the approval of its PD-1 inhibitor ‘Jemperli (dostarlimab),’ and is undergoing discussions with relevant authorities. If approved, Jemperli will become the third PD-1 inhibitor to be approved in Korea after ‘Opdivo (nivolumab),’ and ‘Keytruda (pembrolizumab).’ Unlike the other two drugs that started as a melanoma treatment, Jemperli was approved for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen by the FDA in April last year. In addition, Jemperli was additionally approved for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors in August of the same year. GSK plans to continue adding indications to endometrial cancer in Korea as well. Meanwhile, Jemperli demonstrated its efficacy through the multi-cohort GARNET trial that enrolled patients with dMMR recurrent or advanced endometrial cancer who have progressed on or following prior treatment with a platinum-containing regimen. In the trial, treatment with Jemperli resulted in an objective response rate (ORR) of 43.5%) and a disease control rate of 55.6%. The median duration of response (DoR) had not been reached in these patients, and the probability of maintaining response at six months and 12 months was 97.9% and 90.9%, respectively.
- Company
- Esophageal cancer, added to indication of Opdivo·Keytruda
- by Eo, Yun-Ho Mar 22, 2022 05:53am
- Cancer immunotherapys are advancing into the esophageal cancer area one after another. According to related industries, Opdivo (Nivolumab) and MSD's Keytruda recently were added esophageal cancer indications in Korea. Opdivo obtained final approval from the MFDS last month and Keytruda on the 7th. With this permission, Opdivo can be prescribed as an auxiliary therapy for adult esophageal or GEJ cancer patients with residual pathological diseases after CRT. The efficacy of this drug against esophageal cancer was confirmed through a phase III clinical CheckMate-577 study. As a result of the study, the median PFS period for patients treated with Opdivo after surgery was 22.4 months, twice as long as 11 months for placebo-treated patients. The median treatment period of the Opdivo treatment group was 10.1 months, and the placebo group recorded 9 months. Keytruda is the primary combination therapy. This drug can be prescribed in combination with platinum-based anticancer drugs in the primary of non-removable local progressive or metastatic esophageal cancer and gastroesophageal junction cancer. The effectiveness of Keytruda in esophageal cancer was demonstrated through a phase 3 clinical KEYNOTE-590 study. The combination therapy of Keytruda and 5-FU+Cisplatin demonstrated statistically significant OS and PFS improvements over 5-FU+Cisplatin in all pre-designated study groups. Combination therapy with Keytruda, 5-FU, and Cisplatin reduced the risk of death by about 27% compared to 5-FU+Cisplatin, and the risk of disease progression or death by about 35%. It was analyzed that Keytruda, 5-FU, and Cisplatin reduced the risk of death by 38% and the risk of disease progression or death by 49% compared to 5-FU+Cisplatin in the patient group with PD-L1 expression rate of 10 or higher. Meanwhile, Keytruda recently listed primary lung cancer therapy on the insurance benefit list. Opdivo has recently slowed the expansion of gastric cancer benefits, but has not passed the Cancer Disease Review Committee.
- Company
- Celltrion was fined 13.9 billion won
- by Kim, Jin-Gu Mar 22, 2022 05:53am
- Financial authorities imposed a fine of 13.9 billion won on three Celltrion companies that prepared and disclosed financial statements in violation of accounting standards. The Financial Services Commission held its fifth regular meeting on the 16th and decided on this. The fines decided at the meeting are 6 billion won for Celltrion, 6.04 billion won for Celltrion Healthcare, and 992.1 million won for Celltrion Pharmaceutical. Fines of 415 million won were imposed on two people, including Celltrion CEO, and 483.9 million won on three people, including Celltrion Healthcare CEO, respectively. Penalties imposed on the three Celltrion companies and company managers totaled 13.93 billion won. An accounting firm that was judged to have neglected the audit process was also fined. 1.065 billion won was imposed on EY accounting firms and 410 million won on KPMG. Earlier on the 11th, Securities & Futures Commission under the Financial Supervisory Commission decided on measures such as recommending the dismissal of executives in charge and designating auditors for serious violations in the accounting process of the three Celltrion companies. According to the results of the investigation and supervision, these companies committed violations such as overestimating development costs, sales, and inventory assets, or not listing transaction notes with related parties in their financial statements. The Securities & Futures Commission has decided not to file a complaint with the prosecution, saying it is difficult to say that the violation was intentional. Accordingly, Celltrion was not subject to the Korea Exchange's transaction suspension.
- Company
- Concerns over fungal infection due to COVID-19
- by Eo, Yun-Ho Mar 21, 2022 05:56am
- There is concern about the gap in fungal infections due to the re-proliferation of COVID-19. The most commonly reported fungal infections in COVID-19 patients include COVID-19 associated pulmonic aspergillosis (CAPA), COVID-19 associated mucomycosis (CAM), and Candida auris. These COVID-19-related fungal infections can lead to serious diseases and deaths. If left untreated, CAPA-related morbidity reaches up to 80%, and CAM mortality is close to 100%. CAPA is a secondary fungal infection mentioned as a clinical complication of COVID-19 infection in the government's COVID-19 response guidelines, and CAPA has been confirmed in Korea. ◆The number of patients who need antifungal drugs in Korea also surged According to the KSID Autumn Conference presentation data in November last year, 57.8% (126/218) of 218 patients with severe COVID-19 were treated by ICU, and the cumulative incidence rate of CAPA related to COVID-19 was 4.5% (10/218) and 11.2% (10/89) of COVID-19 patients admitted to intensive care units. In-hospital mobility was 11.9% (26/218) in COVID-19 patients and overall mobility in CAPA patients was 50% (5/10). It was found that CAPA secondary infection affected the survival of COVID-19 patients. COVID-19-related CAPA mainly occurs in severe COVID-19 patients who use ventilators in intensive care units, and patients often show non-specific symptoms, and it is difficult to diagnose because samples need to be collected deep in the lungs. Choo Eun-joo (Professor of Infectious Medicine at Bucheon Hospital at Sooncheonhyang University) said, "As experienced through the COVID-19 pandemic, it is important to preemptively secure drugs necessary for treating acute infectious diseases at the government level. New antimicrobial and antifungal drugs, which are essential for treating infectious diseases, are having difficulties in development around the world despite high clinical needs," she said. Surgical surgery and antifungal agents including Amphotericin B, Posaconazole or Isavuconazole can be used for COVID-19-related CAM treatment, and Voriconazole is not recommended for CAM treatment. Posaconazole has indication for the treatment of CAPA patients in Korea, so if CAPA or CAM is suspected in COVID-19 patients, Cresemba (Isavuconazole) is the only drug that can be used preemptively at the same time as fungal culture. Cresemba is an antifungal agent that has indications for both invasive CAPA and invasive CAM. Cresemba was designated as a national essential drug in June 2021. This drug is licensed and used in March and October 2015, respectively, in the United States and Europe (EMA), but it is not reimbursed in Korea. Professor Choo said, "In Korea, new antibiotics are allowed, but insurance benefits have not yet been registered. There are no antibacterial and antifungal drugs that have entered the right to benefit for the past five to seven years. Drugs necessary to treat fatal infectious diseases should not be evaluated only from an economic perspective, as they play a key role in preventing the spread of infectious diseases as well as the survival of individual patients."
- Company
- 5 companies challenge breast cancer drug Ibrance’s patent
- by Kim, Jin-Gu Mar 21, 2022 05:55am
- Pic. of Ibrance The number of companies challenging the patent of Pfizer’s breast cancer treatment ‘Ibrance (palbociclib)’ has increased to 5. According to the pharmaceutical industry, Boryung Pharmaceutical, Shinpoong Pharm, Daewoong Pharmaceutical, and Samyang Holdings had filed a series of claims to confirm the passive scope of rights on Ibrance’s crystalline form patent. Kwang Dong Pharmaceutical had been the first to challenge the patent on the 3rd of this month. With the additions, a total of 5 companies will be attempting to avoid the crystalline form patent of Ibrance. In the case of Kwang Dong Pharmaceutical, the company had also received approval for a bioequivalence test to develop a generic version of Ibrance. Ibrance’s crystalline form patent will expire on February 8th, 2034. If the companies succeed in avoiding the patent, they will be able to release a generic version after the drug’s substance patent expires on March 22nd, 2027. The substance patent was originally set to expire on January 10th, 2023, but Pfizer had extended the duration of the patent by over 4 years for the time taken on clinical trials and permits. If generic companies additionally challenge to invalidate the extended term of the patent, it is possible that the date of release of the generic products may be further advanced. Until now, generic companies have not aggressively pursued patents challenges for anticancer drugs as the chances of success of the generic is not high due to the high preference of original drugs in the field. Therefore, the development and release of generics after overcoming the patents was not profitable for the companies. Despite the barriers, the reason why so many companies are challenging Ibrance’s patent is because of the reputation built by the drug in the breast cancer treatment market. According to the market research institution IQVIA, Ibrance has continued to expand by double-digit sales every year since it was approved in Korea in August 2016. In fact, Ibrance's sales, which recorded ₩6.6 billion in 2017, then to ₩25.3 billion in 2018, ₩43.7 billion in 2019, ₩57.3 billion in 2020, and to ₩65.6 billion in 2021. Also, the fact that domestic companies started to make an impact in the generic market for anticancer drugs, which had been considered impenetrable, can also be a reason for the increased challenges filed against Ibrance. Recently, Hanmi Pharmaceutical, Samyang Holdings, Boryung Pharmaceutical, and Chong Kun Dang had been showing significant performance in the market. Hanmi had released its generic version of Bayer’s liver cancer treatment Nexavar, ‘soranib,’ Samyang released BMS’s Taxol generic ‘Genexol,’ Chong Kun Dang released generic version of AstraZeneca’s lung cancer treatment Iressa, ‘Iretinib' to chase the market occupied by original drugs.
- Company
- K-Bio has become a global production hub
- by Kim, Jin-Gu Mar 18, 2022 05:55am
- The Korean pharmaceutical bio industry has become a global coronavirus vaccine and treatment consignment production hub. With the consignment production of coronavirus vaccines and antibody treatments in charge, the company will be in charge of consignment production of oral treatments for the supply of underdeveloped countries. On the 17th, the MOHW announced that Celltrion and DongbangFTL were selected as generic producers of the oral corona treatment Paxlovid developed by Pfizer. Celltrion produces finished products and DongbangFTL produces Nirmatrelvir. The products produced here are supplied to 95 underdeveloped countries. MPP, along with two Korean companies, selected a total of 35 companies from 12 countries around the world. There are 19 in India, 5 in China, 1 in Bangladesh, Vietnam, Brazil, Dominican Republic, Mexico, Jordan, Israel, Serbia and Pakistan. In January, International Pharmaceutical Patent Pool also selected three Korean companies as generics of the oral coronavirus treatment developed by MSD. Hanmi Pharmaceutical was selected along with Celltrion and DongbangFTL. Ildong Pharmaceutical is jointly developing another oral treatment candidate material "S-717622" with Shionogi of Japan. Ildong Pharmaceutical plans to produce oral treatments with Shionogi and supply them globally as soon as the clinical trial is completed. It is interpreted that the stable production capacity of Korean companies has been verified by the world over the fact that they have been selected as a producer of oral treatments one after another. Korean pharmaceutical companies are being used as consignment production bases for COVID-19 vaccines and antibody treatments by multinational pharmaceutical companies. In the case of COVID-19 vaccines, five domestic companies have decided to commission production of five global vaccines. SK Bioscience has been producing AstraZeneca and Novavax vacine since last year. Samsung Biologics has signed a contract with Moderna and is producing a coronavirus vaccine. Although it has not yet begun full-scale supply, the Korus Pharm consortium can commission Russian vaccine Sputnik V, while Hanmi Pharmaceutical and Enzychem can commission ZyCoV-D developed by Indian pharmaceutical company Zydus Cadila. In addition, Samsung Biologics is commissioned to produce AstraZeneca Evusheld and Eli Lilly's Bamlanivimab, which are corona antibody treatments. Celltrion has produced and is supplying its own antibody treatment drug Regkirona globally. At the end of last year, it was approved for use in Europe. An official from the pharmaceutical industry said, "Korea has large-scale facilities for consignment production and has high reliability in quality. With the Corona incident, the status of the Korean pharmaceutical bio industry will increase, and the value of the K-bio brand will also increase on the global stage in the future."
- Company
- Largest shareholder of Medipost changed to a private equity
- by Chon, Seung-Hyun Mar 18, 2022 05:55am
- View of Medipost HQ The largest shareholder of the bio venture company Medipost will be changed from the founder and CEO Yoon-sun Yang to a private equity consortium. Medipost plans to receive an investment of approximately ₩140 billion from a private equity fund to invest in its cell and gene therapy business. On the 17th, Medipost announced that it had signed an investment agreement worth ₩140 billion with Skylake Equity Partners and Crescendo Equity Partners. Under the agreement, Medipost will issue a paid-in capital increase through a third-party allotment worth ₩70 billion to Skylake and Crescendo. A total of 374,314 shares will be newly issued. Medipost will issue registered non-guaranteed private Equity Convertible corporate bonds worth ₩35 billion each to Skylake and Crescendo. Skylake and Crescendo etc. will be investing ₩140 billion just in paid-in capital increase and convertible bonds alone. Medipost’s largest shareholder had been CEO Yoon-sun Yang, who had owned 1,001,002 shares (6.16%). However, with the capital increase alone, the number of shares owned by Skylake and Crescendo exceed the number owned by CEO Yang, thereby changing the largest shareholder of the company. In addition, Yang had transferred 400,000 shares to Skylake, etc. at ₩90 billion. When the conversion of convertible bonds to common stocks is complete in addition to the paid-in capital increase the shares bought, Skylake, etc. will own 32.7% of Medipost’s shares. In total, Skylake, etc. is investing ₩230 billion for the acquisition of Medipost shares. Medipost plans to invest ₩85 billion of the secured funds in gene cell therapy CDMO company based in the North American region. Currently, Medipost is in exclusive negotiations with a CDMO company to sign an investment agreement within May this year. The company plans to invest 55 billion won in clinical trials conducted for the osteoarthritis treatment Cartistem and SMUP-IA-01 in the US to accelerate its entry into the US osteoarthritis treatment market. Medipost has pointed to the CDMO business for gene cell therapy as the optimal new The company expects that the business will serve as a production base that can produce and supply clinical regents for Cartistem and SMUP-IA-01 in the US, as well as efficiently manage the manufacture and supply of the company’s products after marketing approval. A Medipost official said, “This funding is significant in that we were able to secure a shareholder who can actively support overseas businesses, based on which we could aggressively promote businesses overseas and maximize corporate value.” An official from Skylake said, “We evaluated Medipost's global potential for global expansion highly as the company owns world-class stem cell screening and culture technology and promising stem cell therapies such as Cartistem, and decided to invest in the company in consideration potential and synergy that will be made with the global cell gene therapy CDMO business and growth." An official from Crescendo said, “We decided to invest in Medipost because we were confident that Medipost could grow into a global champion with Crescendo's overseas business experience and global network, including our ties in the US.” Skylake and Crescendo’s investment will be safeguarded in a depository for one year.
- Company
- Multinational pharmaceutical companies are changing logos
- by Mar 18, 2022 05:55am
- Organon Korea returns after 13 years of absence with a new logo, "Women's Health" starts anew. Multinational pharmaceutical companies are trying to transform their image with new logos. Pfizer entered the unexplored area of mRNA and changed its logo in about 70 years. Sanofi also emphasized "one Sanofi" as an integrated brand logo. Analysts say that multinational pharmaceutical companies are expressing the spirit of science and innovation with new logos as they jump into areas where it is difficult to develop treatments. Sanofi-Aventis Korea announced on the 15th that it will remove the separate brands attached to each division and merge them into a single brand. Until now, the vaccine division has been called Sanofi Pasteur and the specialty care division has been called Sanofi Genzyme. In the future, Pasteur and Genzyme will be excluded and all will be integrated into "Sanofi." However, the existing corporations divided into Sanofi-Pasture and Sanofi-Aventis are not integrated. Old Sanofi logo (left) and New logo (right) The intention is to unite distributed brands and present common goals and identities. Founded in 1973, Sanofi has included companies it has acquired, including Sanofi-Synthelabo, Aventis, and Genzyme, in its business team brand names. Then, in 2019, it announced the improvement of the constitution of the new drug pipeline and began to change. It will boldly give up pipelines with poor growth engines such as chronic diseases and invest heavily in new growth fields such as immunity, rare diseases, and nervous system diseases. In other words, Sanofi's four business units ▲ Sanofi Pasteur (vaccine) ▲ Sanofi Genzyme (specialty care) ▲ General Medicine ▲ Consumer Healthcare is a plan to integrate and expand Pasteur and Genzyme. The logo has also been transformed as part of the first brand integration in Sanofi's history. The new shape, which means innovation, adaptation, and growth, has changed the existing logo, which used to form a circle, to a lowercase logo with two purple dots at the beginning and end of the name. The new logo is inspired by the simple yet dynamic nature of the tech industry. The purple dot on S means the starting point for asking the question What if? The purple dot of i is the end point that results in the discovery of innovative solutions. The new logo represents Sanofi's scientific journey from the starting point to the ending point. Sanofi said, "In the future, we will think and move as a company under a new and common purpose and identity," adding, " we hope the new integrated brand unveiled this time will serve as an opportunity to inform employees, partners, medical experts and patients of Sanofi's identity and orientation." The old Pfizer logo (left) and the new logo (right) Pfizer, which is improving its constitution to develop innovative new drugs, also introduced a new logo for the first time in 70 years. The pill-shaped oval background, which has been representative of Pfizer, has been boldly discarded. The new logo represents a double helix with two tones of blue bands symbolizing Pfizer. This means that the substance of double helix is revealed by unlocking the original pill form. The logo extending upward conveys an upward movement, and the rotating form means "reversing the old reality for innovation." Pfizer, which planned to spin off its patent expiration division and change its logo, finally selected a design produced by Brooklyn Studio Team in the U.S. Just in time, Pfizer succeeded in transforming its image by introducing the COVID-19 vaccine. Pfizer, which commercialized the mRNA-based vaccine for the first time, has also drastically trimmed its pipeline to suit the new logo. It has begun to develop mRNA-based drugs in earnest. mRNA-based drugs are a new mechanism that has just begun commercialization, and there are still many unexplored areas. Old organon logo (left) and new logo (right) Organon, which was spun off from MSD, has started to break away from its past image with a new logo. Founded in the Netherlands in 1923, Organon is the place where the early substance of the immuno-cancer drug Keytruda was developed. It has a history of being absorbed into MSD through a merger with Schering-Plough. About 10 years later, it was separated from MSD again and reborn as an independent corporation. Organon, which focused on women's health in the past, focused on three areas: women's health after independence, chronic diseases, and biosimilars. The name Organon Korea is the same, but it changed the logo in the sense of starting anew. Unlike the old logo, which was a turquoise oval band, the new logo has a circular point in green, blue, and sky blue and a scarlet dash pattern forming a geometric pattern. The central dot means women's health, and the surrounding dots indicate that the company is paying attention to various environments that affect women's health. The dash pattern contains a commitment to improving human life, a vision for a healthier life for all women, and a mission to supply meaningful medicines. The geometric pattern created by gathering dots and dashes means that the company's appearance today and its vision for tomorrow communicate and integrate with each other. Organon Korea said, "In the past, Organon Korea has also made a lot of innovations in women's health," adding, "The new Organon Korea will provide new solutions for women's health, which was relatively unmet."
